Benitec Biopharma (BNTC) director David Friedman files initial Form 3

Rhea-AI Filing Summary

Benitec Biopharma Inc. filed an initial ownership report for director David Matthew Friedman. This Form 3 shows his status as a director but does not list any shareholdings or recent transactions. It serves as a baseline disclosure of his insider position with the company.

Key Terms

Form 3, director, ten percent owner

3 terms

Form 3 regulatory

"filed an initial ownership report for director David Matthew Friedman"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

director financial

"identifies David Matthew Friedman as a director of Benitec Biopharma Inc."

ten percent owner financial

"He is listed solely as a director, with the ten percent owner field marked as not applicable."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 05/28/2026 - 09:09 PM Accepted by SEC EDGAR 05/28/2026 - 09:08 PM Learn about SEC filing dates

FAQ

What does the Benitec Biopharma (BNTC) Form 3 for David Matthew Friedman show?

The Form 3 identifies David Matthew Friedman as a director of Benitec Biopharma Inc. It is an initial ownership report and does not list any shareholdings or recent transactions for him.

Are there any stock transactions reported for David Matthew Friedman in this BNTC Form 3?

No, this Form 3 for Benitec Biopharma Inc. reports no transactions. The transaction fields are empty, indicating no buy, sell, or derivative activity is disclosed in this filing.

Is David Matthew Friedman a ten percent owner of Benitec Biopharma (BNTC)?

No, the Form 3 indicates David Matthew Friedman is not a ten percent owner. He is listed solely as a director, with the ten percent owner field marked as not applicable.

Does the Benitec Biopharma (BNTC) Form 3 disclose any derivative securities for David Matthew Friedman?

No, the derivative section is empty in this Form 3. There are no options, warrants, or other derivative positions reported for David Matthew Friedman in this filing.

What is the purpose of this Benitec Biopharma (BNTC) Form 3 filing?

This Form 3 provides an initial insider ownership report for director David Matthew Friedman. It establishes regulatory disclosure of his status, even though no specific shareholdings or transactions are reported.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Friedman David Matthew

(Last) (First) (Middle)

540 MADISON AVENUE

7TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/22/2026

3. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ David Matthew Friedman	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)